^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DRD2 antagonist

    Related drugs:
    3d
    Transcutaneous Auricular Vagus Nerve Stimulation for Preventing and Treating Postoperative Nausea and Vomiting in Gynecological Laparoscopy Patients: A Randomized Single-Blind Controlled Trial (ChiCTR2600115965)
    P=N/A, N=128, Recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
    New trial
    3d
    Dexmedetomidine versus Chlorpromazine for Patients in ICU with Hyperactive Delirium: A Single-Center, Prospective, Double-Blind, Randomized Controlled Trial (ChiCTR2500114067)
    P=N/A, N=104, Not yet recruiting, Huashan Hospital Fudan University; Huashan Hospital Fudan University
    New trial
    |
    chlorpromazine
    3d
    Preventive Effect of Metoclopramide Combined with Granisetron on Postoperative Nausea and Vomiting in Patients with Patient-Controlled Intravenous Analgesia: A Retrospective Cohort Study (ChiCTR2500113628)
    P=N/A, N=368, Not yet recruiting, Chengdu Seventh People's Hospital; Chengdu Seventh People's Hospital
    New trial
    3d
    Professor Jia Yingjie's "Eliminating Dregs and Cultivating the Root" Acupuncture Method for Treating Postoperative Gastric Emptying Disorder after Whipple Procedure (ChiCTR2500112941)
    P=N/A, N=124, Not yet recruiting, Tianjin Cancer Hospital Airport Hospital; Tianjin Cancer Hospital Airport Hospital
    New trial
    3d
    The Impact of Clozapine and Other Antipsychotic Drugs on the Occurrence of HAP in Hospitalized Schizophrenia Patients: A Prospective, Multicenter Cohort Study (ChiCTR2500112733)
    P=N/A, N=1018, Recruiting, Renmin Hospital of Wuhan University; Renmin Hospital of Wuhan University
    New trial
    3d
    The effects of Propranolol combined with Metoclopramide on stroke-associated pneumonia and related immune indicators: a clinical randomized controlled trial (ChiCTR2500111972)
    P=N/A, N=150, Completed, Quanzhou First Hospital; Quanzhou First Hospital
    New trial
    3d
    Clinical study of the ability of celecoxib combined with olanzapine and paroxetine hydrochloride to improve depression,anxiety and analgesic effects in patients after hemorrhoidal surgery (ChiCTR2500112052)
    P=N/A, N=60, Completed, Affiliated Hospital of Jining Medical University; Affiliated Hospital of Jining Medical University
    New trial
    |
    celecoxib oral • olanzapine
    4d
    Dopamine Agonist Therapy Induced Fatal Pneumocephalus in Giant Prolactinoma. (PubMed, JCEM Case Rep)
    Dopamine agonist (DA) cabergoline (0.25 mg twice weekly) was initiated, and serum prolactin levels reached 3941 ng/mL (SI: 171.3 nmol/L) after 2 doses...Our case and review of 7 published cases of DA-induced pneumocephalus highlights male predominance, median tumor size of 5.5 cm (range, 4-9.5 cm), and onset within 1 to 12 weeks of initiation of DA therapy. Hence, for giant prolactinomas after DA initiation, it is essential to recognize the symptom complex associated with this rare life-threatening complication, pneumocephalus, and offer emergency surgical intervention.
    Journal
    |
    PRL (Prolactin)
    5d
    Cabergoline for the Treatment of Chronic Pain Due to Endometriosis (clinicaltrials.gov)
    P2, N=129, Completed, Boston Children's Hospital | Trial completion date: Jun 2026 --> Jan 2026 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    6d
    The Differences Between Dopamine Agonist-Resistant and -Non-Resistant Prolactinomas: Are There Any Predictors of a Good Response? (PubMed, Biomedicines)
    On the other hand, early radiological tumor shrinkage may predict favorable treatment outcomes. However, new markers of DA resistance, particularly molecular ones, should be identified.
    Journal
    |
    PRL (Prolactin)
    6d
    NOVA3: 52-week Open Label Safety-Tolerability Study (clinicaltrials.gov)
    P3, N=900, Not yet recruiting, LB Pharmaceuticals Inc.
    New P3 trial
    6d
    ITI-ELA-MDD: Neurocircuitry Mechanisms and Efficacy of Lumateperone as Adjunctive Therapy for Major Depressive Disorder and History of Early Life Abuse (clinicaltrials.gov)
    P4, N=50, Not yet recruiting, University of Texas at Austin
    New P4 trial